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Screening for Malignant Pleural Mesothelioma and Lung
Cancer in Individuals with a History of Asbestos Exposure
Heidi C. Roberts, MD,* Demetris A. Patsios, MD,* Narinder S. Paul, MD,* Marc dePerrot, MD,†
Warren Teel, MD,‡ Hamid Bayanati, MD,* Frances Shepherd, MD,§ and Michael R. Johnston, MD
Purpose: We established a screening program for prior asbestos
workers using low-dose computed tomography (LDCT).
Methods: Between March 2005 and October 2007 we performed
LDCT (50–60 mA, 120 kV, 1.25 mm) in 516 asbestos-exposed
individuals. Parenchymal nodules were followed according to lung
cancer screening recommendations, morphology and location of
pleural plaques was noted in detail.
Results: We included 507 men and 9 women (median 60.0 years),
395 (76.6%) were smokers. Annual repeat has been performed in
356 participants. We found plaques in 357 subjects (69.2%), com-
monly calcified (79.6%), flat (86.6%), and symmetric (86.8%), and
mostly involving the costal (96.4%) and diaphragmatic (81.8%)
pleura. Uncommon plaques were lobulated (13.2%), right-dominant
asymmetric (4.5%), or with effusions (0.1%).
We found pulmonary nodules in 371 subjects (71.9%), 91
(17.6%) had at least one nodule 5 mm; 10 growing nodules
were found on annual repeat LDCT. In 41 individuals, plaques
were regarded as atypical; three had new pleural/peritoneal ab-
normalities on annual repeat LDCT. An interim limited computed
tomography of the observed abnormality prompted 10 diagnostic
biopsies, resulting in a diagnosis of six lung cancers, two pleural
mesothelioma and two peritoneal mesothelioma; overall rate of
screen-detected malignancies is 2.1%. There were four interval
cancers, diagnosed after baseline (n  1) or after the annual
repeat (n  3): two pleural and one peritoneal mesothelioma, and
one mixed squamous/small cell carcinoma.
Conclusion: Screening prior asbestos workers detects advanced
malignant pleural mesothelioma and early as well as late stage lung
cancer. We expect to learn more about the appearance of “early
mesothelioma” with continued screening.
Key Words: Asbestos, Pleural plaques, Mesothelioma, Screening,
Computed tomography.
(J Thorac Oncol. 2009;4: 620–628)
Asbestos defines a group of naturally occurring mineralsilicates, which are used for various commercial applica-
tions including fire-proofing and insulation. Asbestos readily
breaks into small dust-like fibers, which are easily inhaled,
resulting in a variety diseases of the respiratory system
including asbestosis, lung cancer, and malignant pleural
mesothelioma (MPM).1,2 To date asbestos has largely been
banned from work and home environments, but many
countries (including Canada) still produce and export as-
bestos under strict regulations and at reduced levels.3,4 As-
bestos-related lung diseases will remain a major health
concern,4,5 mainly due to the long latency between expo-
sure and disease development, but also due to current
accidental asbestos exposures such as during the collapse
of the World Trade Center towers.
Once asbestos exposure has occurred, there is no sec-
ondary prevention of chest diseases or prophylactic treatment
available. There is a direct causal relation between the degree
of asbestos exposure and MPM.6–8 While the risk of lung
cancer slowly declines after smoking cessation, the risk of
MPM progressively increases with time.9 Pleural plaques and
MPM share the same etiology but have a different latency
period (10–20 years for plaques,10–12 20–40 years for
MPM13–15), and even though plaques are not regarded as a
risk factor of MPM, the presence of pleural plaques provides
a risk indicator and thus a window of opportunity for MPM
diagnosis. Low-dose computed tomography (LDCT) has
been studied extensively in high-risk smokers, and can iden-
tify early stage, potentially curable lung cancers,16 although
its effect on mortality remains under investigation. The biol-
ogy of MPM makes this malignancy another potential target
for screening. LDCT is a tool that is readily available for a
detailed assessment of lungs and pleura, but despite ample
published literature on (advanced) MPM,17 the appearance of
“early mesothelioma” is still not known.
The purpose of this study is to assess the utility of
LDCT for the early diagnosis of malignant asbestos-related
lung diseases. The strategy for early lung cancer detection
follows established guidelines.18,19 As MPM originates from
the pleural surface and its presence coincides with pleural
plaques, a focus of this study is to analyze the appearance of
pleural plaques, and to attempt to identify variations in plaque
morphology that might warrant further invasive investiga-
tions to rule out malignancy.
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MATERIALS AND METHODS
Study Population
Between March 2005 and October 2007, 516 individuals
were enrolled. Most (n  338) were recruited in collaboration
with the Occupational Health Clinics for Ontario Workers Inc. in
Sarnia-Lambton, an area that is characterized by record numbers
of asbestos-exposed workers.20 These individuals are regis-
tered by Occupational Health Clinics for Ontario Workers
because of documented asbestos exposure. The remaining
178 participants were referred from workers’ unions and
other contacts, also because of their asbestos exposure.
Inclusion criteria were: asbestos exposure at least 20
years ago or documented pleural plaques (demonstrated on
chest radiographs), maximum age 80 years, in general good
health, in particular no pertinent signs or symptoms of pleural
chest disease. Exclusion criteria were prior cancers (except
nonmelanotic skin cancer).
The study was approved by the Institutional Human
Subjects Review Board and informed consent was obtained.
The participants also completed a detailed questionnaire on
the type and duration of their asbestos exposure and their
occupational history, as well as demographics, family history,
prior medical history, tobacco consumption etc.
Participants underwent LDCT and follow-up of find-
ings as outlined below. If the baseline scan was negative,
participants were invited for an annual LDCT. At the time of
this analysis, 356 individuals have had their annual computed
tomography (CT).
Computed Tomography Scanning
A LDCT scan of the chest was performed on a multide-
tector unit from different manufacturers (General Electric Med-
ical Systems, Toshiba), with different number of detector rows
(4–64), all utilizing helical scanning, low-dose regimens
(40–60 mA, 120 kV) and thin-slice image reconstructions
(1–1.25 mm). Pleural plaques were assessed on images recon-
structed on a low spatial frequency algorithm (“soft tissue
reconstruction”) and displayed at standard mediastinal settings
(Window 400 HU, Level 40 HU), lung nodules on images
reconstructed on a high spatial frequency algorithm (“lung
reconstruction”) and viewed on standard lung settings (Window
1500 HU, Level600 HU). All CT scans were double read, on
a PACS workstation, first by the radiologist on service, followed
by a research fellow for the detailed analysis and description of
the target parameters. Only cross-sectional images were read (no
multiplanar reconstructions). The readers were aware that the
CT scans were from the asbestos study and the research fellow
was not blinded to the initial report.
Pleural plaques were assessed according to their presence
(yes/no), extent (involvement of the pleural surface; mild 25%,
moderate 25 to 50%, severe 50%), location (costal, diaphrag-
matic, mediastinal, fissural pleura), and shape (flat, lobulated).
The presence and extent of calcification was recorded as none,
few (25%), some (25–75%), mostly (75–90%), completely
(90%). We noted the symmetry of plaque distribution and the
presence of pleural fluid. Diffuse pleural thickening was defined
as more than 5 cm in extent along the pleural surface on
transverse CT images, more than 8 cm in extent on craniocaudal
CT images, and more than 3 mm thick.21
Based on the radiologists’ judgment and in discussion
with the thoracic surgeon (MRJ), we followed atypical
plaques. Atypical pleural plaques were defined as (a) plaques
associated with pleural effusions, (b) lobulated and mass-like
plaques and (c) asymmetric distribution of plaques (Figure 1).
As a guideline for follow-up we defined an initial 3- to
6-months LDCT limited to the target area as a guide to
initiate further investigations in the case of growth/change.
Parenchymal nodules were followed according to recom-
mendations from lung cancer screening studies.19 In brief, inde-
terminate nodules are defined as solid nodules 5 mm or larger or
nonsolid nodules 8 mm or larger. These nodules were followed
with a limited LDCT scans 3 to 6 months after the baseline CT.
Further investigations (e.g., CT guided biopsy) were initiated if
the nodule under surveillance had grown.
Further investigational procedures were recommended
based on suspicious findings as baseline, or following growth
at the 3 to 6 months or annual follow-up examination (Table
2, Figure 1). They ranged from CT-guided biopsy (e.g., of the
lung nodules), to thoracocentesis (e.g., of pleural nodularity
and effusion) to ultrasound (e.g., of new peritoneal nod-
ules)—assuming that the ultrasound would have been fol-
lowed by biopsy if required. The kind of investigational
procedure was dictated by the type of abnormality, its loca-
tion and accessibility, following standard of care.
RESULTS
The findings and the follow-up of the screened individ-
uals are summarized in Figure 1.
Study Population
The demographics of the study population has been
summarized in Table 1. The average pack-years of the current
and former smokers was 23.4  1.0.
Asbestos exposure was documented in 510 (98.8%)
individuals, 249 (48.2%) had known pleural plaques (mostly
documented on chest radiographs); only six individuals had
no knowledge of prior asbestos exposure and were enrolled
based on the presence of pleural plaques alone. The type of
asbestos fiber to which the subjects were exposed was re-
ported as unknown (n  230), all (n  16) or a mixture of
different asbestos types (n  66), mostly amphiboles (n 
19), chrysotiles (n 84), crocidolites (n 12), or asbestos in
blue mud cement (n  89).
Pleural Plaques
Of the 516 individuals, 357 (69.2%) had at least mild
plaques, 159 (30.8%) had no plaques at baseline. Most common
plaque location was the costal pleura (n  344, 96.4% of
357), followed by the diaphragmatic (n  292, 81.8%) and
the mediastinal pleura (n  107, 30.0%). The fissures were
involved in 7 cases (2.0%).
In 309 cases (86.6% of 357) all plaques were flat; in 47
cases (13.2%) we found at least one lobulated plaque (Figure
2). Diffuse pleural thickening was present in 1 case (0.3%).
Seventy-three of the 357 individuals (20.4%) with pleural
plaques showed no calcifications; 44 subjects (12.3%) had few,
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110 (30.8%) minor calcifications. In 101 cases (28.3%) plaques
were mostly and in 29 subjects (8.1%) completely calcified.
Plaques were associated with effusions in three indi-
viduals at baseline (0.6%). In one subject, the pleural effusion
was associated with nodular pleural thickening, although a
subsequent biopsy revealed no malignancy. In the other two
cases with pleural effusions, a remote CT scan confirmed
stability for several years. Another subject had aspiration of
his new pleural effusion seen on the annual LDCT, no
malignant cells were found.
In 310 subjects, the distribution of plaques was sym-
metric (86.8%). Of the 46 cases (12.9%) with asymmetric
distribution, 32 were left dominant (70%).
Based on combined radiologic/surgical judgments, 41
(7.9%) individuals were considered to have atypical pleural
plaques at baseline, which were followed as outlined above. In
addition, 13 of these subjects also had pulmonary nodules that
required further CT surveillance (see below).
Of the 356 study participants who have had an annual
LDCT to date, one developed new pleural thickening and one
a new pleural effusion (see above). The other 252 study
participants (99.2%) demonstrated no change.
Parenchymal Nodules
One or more pulmonary nodules were detected in 371
individuals (71.9%). In 91 cases (17.6%), at least one nodule
was 5 mm or larger that required a limited LDCT in 3 to 6
months. We did not find any nonsolid nodules 8 mm or larger.
Thirteen of these 371 individuals had atypical plaques as well.
In the 356 annual LDCT studies performed we found
10 new or growing nodules (2.8%), which prompted 1 im-
mediate biopsy and 9 limited follow-up LDCT.
Follow-Up Procedures
The recommended interventions are listed in Table 2.
Immediate investigation of abnormal baseline findings was
recommended in five cases: a pleural effusion with thickened
pleura was aspirated and revealed no malignancy; an imme-
diate biopsy of a 2 cm parenchymal nodule failed because of
its location, positron emission tomography was negative and
the nodule remains stable 13 months after baseline; biopsy of
a large pleural/diaphragmatic mass revealed an advanced
MPM (Figure 3); biopsy of a large lung mass showed small
cell carcinoma. One recommended follow-up (ultrasound) of
peritoneal nodules was delayed for several months for un-
known reasons; the patient was eventually diagnosed with an
advanced peritoneal mesothelioma.
Immediate investigation of an abnormality found on
annual LDCT was recommended in 3 participants, one had
new abdominal soft tissue masses, and was subsequently
diagnosed with a malignant peritoneal mesothelioma (Figure
4), one had a growing nodule diagnosed as adenocarcinoma,
and one had a new pleural effusion, ultrasound-guided aspi-
ration did not reveal malignancy.
positive baseline
n = 123
3 – 6 months f/u
n = 116
stable c/w
remote CT
n = 2
bx failed
PET neg
stable on f/u
advanced
MPM
(Fig. 3)
small cell ca
benign pleural fluid
MPM
(Fig. 5)
adeno-ca
n = 2
squamous
cell ca
n = 1
insufficient
material,
under 
surveillance
biopsy
n = 5new/growing
nodule(s)
n = 10
3 – 6 months f/u
n = 10
malignant peritoneal
mesothelioma
n = 1
(Fig. 4)
benign pleural 
fluid
stable or 
decreased
n = 6
increased
n = 1
squamous cell ca
n = 1
both
n = 13
atypical PP
n = 41
nodule ≥5mm
n = 91
total screened
n = 516
negative baseline
n = 393
pleural effusion
n = 3
immediate biopsy
n = 4
performed to date n = 356
performed to date n = 7
immediate bx
n = 3
biopsy n = 1
stable or decreased
n = 111
annual repeat
n = 504
increased
n = 5
new pleural/
peritoneal
soft tissue/effusion
n = 3
peritoneal nodules
u/s delayed
malignant peritoneal 
mesothelioma
n = 1
adeno-ca
n = 1
FIGURE 1. Overview of the follow
up and outcome of the study partici-
pants following the baseline study
and the annual repeat study. PP,
pleural plaques; MPM, malignant
pleural mesotheliomas; f/u, follow-up.
TABLE 1. Demographics of the Study Population
n %
Total 516
Men 507 98.3%
Women 9 1.7%
Age years 60 (32–83)
Smoker
Current 104 20.2%
Former 291 56.4%
Never 121 23.4%
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Interim follow-up scans of atypical pleural plaques
and/or indeterminate nodules were performed 3 to 6 months
after baseline in 116 cases. In five cases, the abnormality had
grown and biopsy was recommended. Four revealed malig-
nancy: MPM (Figure 5), stage 1 adenocarcinoma, squamous
cell carcinoma (unstaged), and an unstaged adenocarcinoma;
the fifth biopsy yielded insufficient material, the nodule is
under surveillance and for the purpose of this analysis re-
garded as benign.
Interim follow-up of plaques or nodules was recom-
mended from the annual LDCT in 10 cases, 9 for nodules and
1 for new pleural thickening. Seven follow-up examinations
have been performed to date, with five nodules decreased or
stable, and one increasing in size; this was subsequently
biopsied and revealed a stage 1 squamous cell carcinoma.
One new focal pleural thickening had decreased on the 6
month follow-up CT. The remaining three follow-up exams
are not yet scheduled.
The number of invasive procedures recommended from
baseline studies was 10/516 (1.9%), 7 revealed malignancy;
the malignancy rate is 7/10 (70%). The rate of invasive
procedures from annual scans was 4/356 (1.1%), 3 revealed
malignancy and the malignancy rate was 3/4 (75%).
Malignancies
Table 2 provides an overview of the malignancies. We
identified six lung cancers, two MPM and two malignant
peritoneal mesothelioma on baseline and annual scans (seven
prevalence and three incidence malignancies), for an overall
malignancy rate of 2.1%. In addition, we are aware of four
interval cancers, diagnosed after baseline (n  1) or after the
annual repeat (n  3): two pleural and one peritoneal me-
sothelioma, and one squamous cell carcinoma with a small
cell carcinoma focus in an infracarinal lymph node. All
malignancies were found in smokers who had an average 31
pack-year history. Three screen-detected lung cancers were
stage 1 NSCLC (one squamous cell carcinoma, two adeno-
carcinoma), one a small cell carcinoma. Two screen-detected
lung cancers are unstaged (one recently diagnosed; the other
patient’s health was too poor for any further procedures).
Two of the screen-detected lung cancers are lost to follow-up;
the patients with stage 1 lung cancer are still alive to date.
We found two MPM and two peritoneal mesothelioma.
One MPM was advanced at the time of diagnosis; the other
MPM seemed early stage but grew aggressively during the
presurgical staging (Figure 5). Two of the patients with
mesothelioma underwent explorative surgery, none under-
went surgery for treatment. All mesothelioma patients died
soon after diagnosis, maximal survival was 9 months.
DISCUSSION
We established a screening program for the detection of
asbestos-related MPM and lung cancer, using LDCT of the
chest. In addition to the lung parenchyma, we focused on the
appearance of pleural plaques, to detect abnormalities which
might warrant further investigation to exclude a pleural neo-
plasm. We identified atypical pleural morphology as lobu-
lated plaques, asymmetric in distribution (in particular when
right dominant), and plaques along the mediastinal pleura.
Two MPM and two malignant peritoneal mesothelioma were
detected. Lung nodules were followed up according to lung
cancer screening protocols, resulting in the diagnosis of six
lung cancers.
Malignant pleural mesothelioma has a highly specific
causal relationship with asbestos, more than 80% of MPM are
attributable to asbestos exposure.13–15,22,23 The emphasis for
development of MPM seems to be on latency rather than
dose24: the latency period from asbestos exposure is 20 to 40
years,13–15,25 which is reflected in the enrollment criteria for
our study.
MPM is associated with a median survival time of 1 year
from symptom onset, which suggests that methods to detect this
malignancy earlier are needed. Symptoms are nonspecific and
may similar to lung cancer.14,15,23 It can be difficult to make a
definite diagnosis of MPM even in advanced cases.14,15 The
radiologic appearance of “early mesothelioma” is as yet un-
known, as to date, most radiology literature has focused on
diagnostic confirmation and staging.17
Pleural plaques refer to circumscribed pleural thicken-
ing or fibrosis, which can be found in up to 50% of workers
exposed to asbestos26,27: in our series pleural plaques were
seen in 69% of subjects. Plaques are regarded as a reliable
indicator for asbestos exposure,11,12,28 to the extent that we
enrolled individuals with documented pleural plaques even if
FIGURE 2. A, low-dose computed
tomography (LDCT) images from
different study participants. Post
prior asbestos exposure, evidence of
flat, partly calcified pleural plaques
along the costal pleural surface (ar-
row). B, Post prior asbestos expo-
sure, evidence of lobulated pleural
plaques along the costal pleural sur-
face, without calcifications (arrow).
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their asbestos exposure was unknown. There is a direct
relation between the intensity of asbestos exposure and the
total area of the pleura involved by plaque formation.29
The relationship between pleural plaques and malig-
nant mesothelioma is not completely understood. Both
share a common etiology,30,31 and autopsy series indicate
that plaques are associated with an increased risk of
mesothelioma.27 It has been suggested that detection of pleu-
ral plaques may allow the identification of people at risk for
mesothelioma,28 but longitudinal studies to confirm this are
lacking. Pleural plaques are usually detected only by radio-
logic examination, as they are frequently asymptomatic, and
do not typically impair pulmonary function.32–35 Diffuse
pleural thickening is less common than pleural plaque for-
mation.31 It usually develops 20 to 40 years after first asbestos
exposure and may result in a restrictive or constrictive phys-
iologic defect.32,36
Pleural plaques seem circumscribed on cross-sectional
imaging. Plaque calcifications may be present in approxi-
mately 20%17 to 70%21: in our series plaques contained
calcifications in 80%. Plaques are usually bilateral (80%)
and unilateral findings are more often left-sided than right-
sided,37 which was also found in our study.
Pleural plaques are rarely associated with fluid.38 Pleu-
ral effusions are earlier markers and occur within 10 years of
asbestos exposure, may last several months and spontane-
ously resolve.26 MPM presents in up to 74% of cases with
fluid alone.14 Thus, the presence of pleural fluid in our
population with remote asbestos exposure was regarded as
atypical. Two pleural effusions found at baseline were stable
when compared with remote CT studies and two pleural
effusions had no evidence of malignancy in the aspirated
fluid. Given that pleural fluid cytology is often negative even
in proven cases of MPM,39 we continue to follow these
individuals closely.
Both location and imaging features of pleural plaques
overlap with the description of MPM on CT14: the most
common radiologic pattern of MPM is localized or diffuse
pleural masses (92%), and 20% have other signs of asbestos
exposure. Thickening of the interlobar fissure has been re-
ported in 86%14 in MPM. Per definition, pleural plaques
originate from the parietal pleura,27 and thus should not
involve the fissures, which are covered by visceral pleura
only. However, thickening of the fissures after asbestos ex-
posure has been described in the literature in 12% of cases,21
and there is indication in the literature that a small percentage
of plaques are indeed visceral,40 which was confirmed in our
series in 2% of subjects.
Since pleural plaques and MPM overlap in their pre-
sentation, one focus of this study was to define the appear-
ance of pleural soft tissue masses that can no longer be safely
interpreted as typical pleural plaques and may be indicative of
an early mesothelioma. We were not able to identify any
single feature of constellation of CT changes that was pre-
dictive of MPM in the patients who developed this malig-
nancy after their initial screening scan. Furthermore, screen-
ing did not lead to the early diagnosis of mesothelioma in any
FIGURE 3. Baseline low-dose com-
puted tomography (LCDT) (left) of
a 64-year-old male shows a hypoat-
tenuated/necrotic mass along the
right pleura/diaphragm (arrows),
which is better visualized on the
subsequent contrast-enhanced com-
puted tomography (CT) (right). Bi-
opsy revealed a malignant mesothe-
lioma.
FIGURE 4. Annual repeat screening low-dose computed
tomography (LDCT) of a 68-year-old man. The annual re-
peat demonstrates intra-abdominal, prehepatic soft tissue
nodules which were not present on the baseline. Subsequent
investigations revealed a malignant peritoneal mesothelioma.
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cases. One MPM found in our study had invaded the dia-
phragm and another quickly progressed during the staging
period (Figure 5) and at that time was no longer operable. An
extremely rapid growth of MPM has been previously de-
scribed.41–43
As expected, the number of lung cancers found in our
population exceeded the number of MPM. It has been re-
ported that for every one mesothelioma case there are two
asbestos-related lung cancer cases.44 Smoking has a strong
synergistic interaction with asbestos,45,46 and an elevated lung
cancer risk may also be associated with bilateral pleural
plaques alone.47 Smoking is not related to the risk of devel-
oping MPM,14,16,27,48 and thus was not required to enroll in
our study. Consequently, the lung cancer rate is rather low at
1.1%, a rate that is similar to that reported by Fasola et al.38
in a similarly designed study. The lung cancer prevalence is
much higher (4.3%) when high-risk smokers and asbestos-
exposed individuals are screened.49 In fact, in the study
reported by Fasola et al.,38 no mesothelioma was found
among 1045 subjects screened, underlining the different risk
profile of the 2 malignancies. Our study had a similar per-
centage of smokers (77%) as other studies that have reported
75% to 87% smokers.38,49,50
The prevalence of lung nodules (72%) and the rate of
positive baseline scans (18%) is similar to other screening
studies.18,51,52 One quarter of our invasive interventions were
performed for benign lesions, which is lower than the 52%
intervention rate reported in a similar screening study.38
To our knowledge, this is the first screening study of
prior asbestos-exposed individuals targeting the early diag-
nosis of MPM, and focusing on the morphology of pleural
plaques. Several other screening studies have been conducted
in this high-risk population, focusing on the asbestos-related
parenchymal disease (asbestosis),49 or on lung nodules and
lung cancers as the primary end point.38,50,51,53 Only one
study reported on a pleural mesothelioma found in the screen-
ing study,50 but its appearance and stage were not described.
Our findings suggest that LDCT can find MPM in asymp-
tomatic individuals; however, whether LDCT will result in
the diagnosis of an “early” MPM where treatment may be
offered with curative intent still has to be addressed. Our
experience reflects the well-know aggressive features of
MPM, four interval cancers are known to date, three of those
were mesothelioma. The current screening regimen may need
to be adjusted; in particular, the biennial screening interval
following a stable annual CT is currently under discussion.
Most importantly, there is need for a biomarker as an inde-
pendent risk indicator (see below), which then would allow
screening individuals at very high risk for mesothelioma at
shorter intervals, possibly utilizing minimum dose/thicker
FIGURE 5. A, Baseline low-dose
computed tomography (LDCT) of a
71-year-old man demonstrated
asymmetric pleural plaques, right
dominant (arrow). A 3 months fol-
low-up was recommended. B, Three
months later, there is interval devel-
opment of a moderate pleural effu-
sion (asterisk), (C) as well as new
nodules along the pleural surface
(arrow). Subsequent thoracocentesis
and drainage to dryness was posi-
tive for mesothelioma. D, The con-
trast-enhanced staging computed
tomography (CT) 2 months later
showed recurrence of the pleural
effusion, increase in the previously
seen pleural effusions as well as new
soft tissue nodules along the medi-
astinal surface and along the azygos
lobe (arrow).
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slice regimens to achieve sufficient signal/noise ratio with
reduced radiation dose. For certain mesothelioma types, se-
rum mesothelin-related protein is a potential biomarker for
detection and treatment monitoring.54
Our study is limited by a short observation period.
Continued screening will allow us to appreciate changes in
plaque appearance, and interim mesothelioma diagnoses will
provide information on its early presentation. Software de-
velopments will help in the analysis of pleural abnormalities
and interval changes.55 We have not included magnetic res-
onance imaging because of limited availability and high
expense. T2-weighted magnetic resonance imaging images in
particular allow discrimination between pleural plaques and
malignant mesothelioma,30,56,57 and might help to character-
ize suspicious plaques. Positron emission tomography also
holds promise for mesothelioma staging,58 but its place in the
early diagnosis has not yet been assessed.
A successful screening program includes an effective
treatment to improve the prognosis of the early detected
disease. Unfortunately, treatment options for MPM are lim-
ited. Promising advances include trimodality treatment con-
sisting of chemotherapy followed by extrapleural pneumo-
nectomy and hemithorax radiation.59–61
In summary, we have developed a screening program in
asbestos-exposed individuals, and have assessed the appear-
ance of pleural plaques. Advanced pleural and peritoneal
mesothelioma as well as early and late stage lung cancers
have been found. With continued screening and observation
of changes in plaque morphology we expect to learn about the
“early mesothelioma.”
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